AR112473A1 - PROCESS TO PREPARE PURIFIED LEVODOPA AMIDE - Google Patents
PROCESS TO PREPARE PURIFIED LEVODOPA AMIDEInfo
- Publication number
- AR112473A1 AR112473A1 ARP180102330A AR112473A1 AR 112473 A1 AR112473 A1 AR 112473A1 AR P180102330 A ARP180102330 A AR P180102330A AR 112473 A1 AR112473 A1 AR 112473A1
- Authority
- AR
- Argentina
- Prior art keywords
- dopamide
- pharmaceutically acceptable
- prepare purified
- processes
- levodopa
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
- C07C231/24—Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Procesos de purificación a gran escala de una sal de L-dopamida aceptable desde el punto de vista farmacéutico y procesos para elaborar una L-dopamida purificada aceptable desde el punto de vista farmacéutico, y sales de L-dopamida aceptables desde el punto de vista farmacéutico sustancialmente libres de L-dopa. Dichos procesos son útiles para proporcionar L-dopamida para el tratamiento de trastornos neurodegenerativos, tales como enfermedad de Parkinson.Large-scale purification processes of a pharmaceutically acceptable salt of L-dopamide and processes for making a purified pharmaceutically acceptable L-dopamide, and pharmaceutically acceptable salts of L-dopamide substantially free of L-dopa. Such processes are useful in providing L-dopamide for the treatment of neurodegenerative disorders, such as Parkinson's disease.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548108P | 2017-08-21 | 2017-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112473A1 true AR112473A1 (en) | 2019-10-30 |
Family
ID=63683237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102330 AR112473A1 (en) | 2017-08-21 | 2018-08-15 | PROCESS TO PREPARE PURIFIED LEVODOPA AMIDE |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR112473A1 (en) |
| WO (1) | WO2019038638A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| ES2836325T3 (en) | 2014-03-13 | 2021-06-24 | Neuroderm Ltd | Compositions of the dopa decarboxylase inhibitor |
| WO2020035853A1 (en) * | 2018-08-15 | 2020-02-20 | Neuroderm, Ltd. | Process for preparing purified levodopamide free base |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004069146A2 (en) * | 2003-02-07 | 2004-08-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-dopa amide derivatives and uses thereof |
| RU2018119194A (en) | 2015-11-24 | 2019-12-25 | Нейродерм Лтд. | PHARMACEUTICAL COMPOSITIONS CONTAINING AMEO LEVODOPA AND THEIR APPLICATIONS |
-
2018
- 2018-08-15 AR ARP180102330 patent/AR112473A1/en unknown
- 2018-08-15 WO PCT/IB2018/056126 patent/WO2019038638A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019038638A1 (en) | 2019-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112473A1 (en) | PROCESS TO PREPARE PURIFIED LEVODOPA AMIDE | |
| AR110747A1 (en) | 5-METHYL-1,2,4-OXADIAZOL-3-ILO COMPOUNDS | |
| ECSP18078877A (en) | ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | |
| IL276493A (en) | Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease | |
| AR111693A1 (en) | 5-METHYL-1,3,4-OXADIAZOL-2-ILO COMPOUNDS WITH OGA INHIBITORY ACTIVITY | |
| CO6630139A2 (en) | Aptámeros par b-bgf and its use in the treatment of diseases and disorders mediated by b-ngf | |
| CO2018013585A2 (en) | Pyrimidin-2-ylamino-1h-pyrazoles as inhibitors of lrrk2 for use in the treatment of neurodegenerative disorders. | |
| CL2020001343A1 (en) | Novel catecholamine prodrugs for use in the treatment of parkinson's disease. | |
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| EA201791802A1 (en) | CROSSED DIHYDRO-4H-PYRAZOLO [5,1-c] [1,4] OXASYNYL COMPOUNDS AND ANALOGUES FOR THE TREATMENT OF CNS DISEASES | |
| UY35012A (en) | ALCOXIPIRAZOLES AS SOLUBLE CYCLING GUANILATE ACTIVATORS | |
| AR112472A1 (en) | FORM OF LEVODOPA AMIDA CRYSTALLINE SALTS AND METHODS FOR PREPARING AND USING THEM | |
| CU20160151A7 (en) | 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHYDROPIRANE [3,4-d] [1,3] TIAZIN-8a (8H) -IL-1,3-TIAZOL-4-ILAMIDAS | |
| MD3416631T2 (en) | Therapeutic agents for neurodegenerative diseases | |
| CL2019001512A1 (en) | Treatment of neurological diseases. | |
| CO2017003321A2 (en) | Lysine gingipain inhibitors | |
| CU20200041A7 (en) | SUBSTITUTE IMIDAZOPYRIDINE AMIDES | |
| MX2019005779A (en) | Methods of treating developmental disorders and/or seizure disorders with flupirtine. | |
| AR112683A1 (en) | CRYSTAL FORM BASED FREE OF LEVODOPA, ITS ADDITION SALT AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT | |
| UY36274A (en) | BICYCLIC COMPOUNDS REPLACED AS SELECTIVE AGONISTS OF S1P1 RECEPTOR ACTIVITY COUPLED TO PROTEIN G | |
| AR092247A1 (en) | INHIBITORS OF THE B-SECRETASE | |
| GT201700227A (en) | AMINO HYDROTIAZINE DERIVATIVES FUSED WITH TETRAHYDROFURAN WHICH ARE USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | |
| RU2020115710A (en) | THERAPEUTIC AGENTS FOR NEURODEGENERATIVE DISEASES | |
| CL2018001633A1 (en) | Compositions of polyhydroxylated benzophenones and methods for the treatment of neurodegenerative disorders | |
| PE20171621A1 (en) | THERAPEUTIC AGENT FOR FRONTAL LOBE DYSFUNCTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |